Amgen's (AMGN) new cholesterol drug Repatha reduced the risk of heart attacks, strokes and other heart-related health problems by 15% compared to a placebo, according to results from a highly anticipated, 27,000-patient clinical trial reported Friday.
The company believes the study results meet that goal.
In the FOURIER study, Repatha dropped LDL cholesterol in patients by 59% compared to placebo.
The main goal, or primary endpoint, of the FOURIER study was to determine if longer-term use of Repatha could reduce the risk of cardiovascular death, heart attack, stroke, hospitalization for unstable angina or coronary revascularization.
A key secondary endpoint of the study narrows the list of bad patient outcomes to cardiovascular death, heart attack and stroke.